Name
Aktsiaselts MAGNUM
Registry code
12371718
VAT number
EE101106531
Type
AS - Joint Stock Company
Status
Registered
Foundation date
01.11.2012 (12)
Financial year
01.05-30.04
Capital
25 000.00 €
Activity
82991 - Other business support service activities n.e.c. 70221 - Business and other management consultancy activities 63111 - Data processing, hosting and related activities 77401 - Leasing of intellectual property and similar products, except copyrighted works 69202 - Bookkeeping, tax consulting
-
-
-
-
-
-
-
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| MM Pharma OÜ 14080511 | 100% - 25 000.00 EUR | - | - | Shareholder |
| Mari Krass
| - | Board member | - | |
| Marika Pensa
| - | Board member | - | |
| Veiko Vetto
| - | Board member | - | |
| Ahti Kallikorm
| - | - | - | Board member |
| Anu Sofia Kuks
| - | - | - | Board member |
| Margus Kähri
| - | - | - | Board member |
| Kristel Volver
| - | - | - | Board member |
| Omanikukonto: MARGUS LINNAMÄE
| - | - | - | Chairman of the board |
| MM Grupp OÜ 10515366 | - | - | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Magnum Dental OÜ 10351798 | 75% - 7 500.00 EUR | - | - | |
| Allium UPI OÜ 11331786 | 100% - 2 556.00 EUR | - | - | |
| MAGNUM LOGISTICS OÜ 11331792 | 100% - 2 556.00 EUR | - | - | |
| MAGNUM MEDICAL OÜ 11332521 | 100% - 2 556.00 EUR | - | - | |
| Apteegi Beauty OÜ 14416750 | 100% - 2 500.00 EUR | - | - | Founder |
| Allium Pharma OÜ 14192368 | 100% - 2 500.00 EUR | - | - | |
| TPA Narva Apteegid OÜ 14160210 | 100% - 2 500.00 EUR | - | - | |
| OÜ Narva-Jõesuu Apteek 11820456 | 49% - 2 454.00 EUR | - | - | |
| Aktsiaselts Magnum Veterinaaria 10007517 | 100% - 223 051.00 EUR | - | - | Shareholder |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q4 | - | 647 137.58 € | 675 347.58 € | 79 |
| 2024 Q3 | - | 466 285.81 € | 492 471.25 € | 80 |
| 2024 Q2 | - | 427 025.68 € | 438 963.39 € | 79 |
| 2024 Q1 | - | 459 563.01 € | 469 709.41 € | 75 |
| 2023 Q4 | - | 797 194.51 € | 813 399.34 € | 77 |
| 2023 Q3 | - | 461 335.86 € | 477 901.87 € | 74 |
| 2023 Q2 | - | 405 269.14 € | 414 596.51 € | 71 |
| 2023 Q1 | - | 381 689.97 € | 397 292.13 € | 74 |
| 2022 Q4 | - | 460 717.23 € | 471 505.5 € | 69 |
| 2022 Q3 | - | 353 771.88 € | 371 647.96 € | 71 |
| 2022 Q2 | - | 317 993.52 € | 330 082.21 € | 74 |
| 2022 Q1 | - | 302 043.38 € | 313 615.29 € | 74 |
| 2021 Q4 | - | 398 339.79 € | 415 324.35 € | 70 |
| 2021 Q3 | - | 308 596.82 € | 324 244.07 € | 69 |
| 2021 Q2 | - | 285 653.78 € | 301 710.97 € | 66 |
| 2021 Q1 | - | 273 921.56 € | 286 871.06 € | 73 |
| 2020 Q4 | - | 366 509.27 € | 386 559.16 € | 71 |
| 2020 Q3 | - | 295 043.29 € | 312 219.18 € | 71 |
| 2020 Q2 | - | 321 029.75 € | 336 180.61 € | 68 |
| 2020 Q1 | - | 284 193.47 € | 293 202.33 € | 71 |
